Exelixis (EXEL)
(Delayed Data from NSDQ)
$22.40 USD
-0.15 (-0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.40 USD
-0.15 (-0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.
TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
TriMas Corporation (TRS) is scheduled to report fourth-quarter 2014 results on Feb 28, before the opening bell.
Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.
Forget Alexion, Buy these 4 Biotech Stocks Instead
by Arpita Dutt
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Forget Gilead, Buy These 5 Biotech Stocks Instead
by Arpita Dutt
With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.
ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.
Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
by Zacks Equity Research
Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
Exelixis (EXEL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL).
Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.
Ecolab (ECL): What's in the Cards this Earnings Season?
by Zacks Equity Research
St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.
Buy 4 Stocks Riding High on Superb Earnings Acceleration
by Tirthankar Chakraborty
If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.